Marvel Biosciences has announced encouraging preclinical results for its lead drug candidate, MB-204, in a Fragile X Syndrome (FXS) study conducted through the FRAXA Drug Validation Initiative (FRAXA-DVI) in collaboration with the FRAXA Research Foundation. The findings mark another milestone in the development of MB-204, demonstrating significant improvements in behavioural and cognitive function while further strengthening its potential as a treatment for Autism Spectrum Disorder (ASD) and related neurodevelopmental disorders.

The latest data adds to previously reported positive outcomes in Rett syndrome (Mecp2) and the Oprm1 autism model, making Fragile X syndrome the third independent preclinical model in which MB-204 has shown robust efficacy. According to the company, the cumulative evidence reinforces the scientific rationale for advancing the investigational therapy toward clinical trials while expanding its potential application across multiple orphan neurological diseases with high unmet medical needs.

Fragile X syndrome, caused by mutations in the FMR1 gene, is the most common inherited cause of intellectual disability and one of the leading single-gene causes of autism spectrum disorder. The rare genetic disorder affects approximately one in 7,000 males and one in 11,000 females and currently has limited therapeutic options.

The study evaluated MB-204 in FMR1 knockout mice, with animals receiving low- and high-dose oral treatments once daily for approximately two weeks. Researchers assessed behavioural and cognitive performance using a range of established neurological tests before re-evaluating the animals two weeks after treatment ended to determine whether therapeutic benefits persisted.

Results showed that MB-204 restored multiple behavioural and cognitive functions towards normal levels. The high-dose treatment group demonstrated the strongest and most consistent improvements, with significant gains observed in locomotor activity, recognition memory, self-grooming behaviour, nesting activity and anxiety-related responses. Both treatment groups also showed marked improvements in novel object recognition, an important indicator of cognitive performance.

Notably, the study also demonstrated a sustained carry-over effect after treatment cessation. Animals in the high-dose group continued to exhibit significant improvements in locomotor activity, self-grooming and recognition memory two weeks after treatment had ended, suggesting that MB-204 may provide durable therapeutic benefits beyond the dosing period.

Dr. Mark Williams, Chief Scientific Officer of Marvel Biosciences, said, "This is now the third ASD model and second independent group that has demonstrated the potential of MB-204 to restore behavioural and cognitive function to near normal levels in mice regardless of the genetic cause of the neurodevelopmental disorder. We also confirmed a carry-over effect in a second model, suggesting MB-204 has a very attractive target product profile. We are grateful to FRAXA for this collaboration and look forward to advancing MB-204 to the clinic."

Marvel Biosciences said the latest findings further validate MB-204's mechanism of action and significantly strengthen the preclinical evidence supporting its clinical development. The company has also completed preclinical evaluation of MB-204 in a Shank3 model of Phelan-McDermid syndrome and is awaiting final statistical analysis, with results expected to be announced in a future update.

Based in Calgary, Marvel Biosciences is developing novel therapies for neurological and neurodevelopmental disorders. Its lead candidate, MB-204, is a fluorinated derivative of istradefylline, an approved Parkinson's disease treatment and the only commercially available adenosine A2A receptor antagonist, which the company believes could offer broad therapeutic potential across multiple autism-related and rare neurological conditions.